Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Deletion Mutation Linked to Prostate Cancer

By Biotechdaily staff writers
Posted on 24 Sep 2002
Investigators have found that a deletion mutation on the MSR1 (macrophage scavenger receptor 1) gene is linked to the likelihood of men of both African-American and European ancestry to develop prostate cancer. More...
The finding was reported in the September 16, 2002, issue of Nature Genetics.

In a collaborative effort, researchers from Johns Hopkins University (Baltimore, MD, USA) and Wake Forest University (Winston-Salem, NC, www.wfu.edu) evaluated the role of MSR1 in a large number of subjects from multiple populations. Initially, eight mutations in MSR1 were found in 159 patients from families that averaged five or more men with prostate cancer. Ultimately they found mutations in 4.4% of Caucasians who had prostate cancer, compared to 0.8% of those found negative in prostate cancer screening. A different mutation of the gene was found in 12.5% of African-American men with prostate cancer, compared to 1.82% of unaffected men.

Both differences were statistically highly significant. "One of the mutations leads to prostate cancer that has rapid metastasis,” said the study's first author, Dr. Jianfeng Xu, associate professor at Wake Forest University. "We provide novel genetic evidence that MSR1 may play an important role in prostate cancer susceptibility.”

Just as there are a number of breast cancer genes, the MSR1 gene probably will turn out to be one of a number of genes linked to prostate cancer. However, the authors suggest that MSR1 shows the strongest gene linkage to inherited prostate cancer risk thus far.




Related Links:
Johns Hopkins University
Wake Forest University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.